Clinical trials: Healthy Patients
Healthy, Renal Impairment
A Safety, PK, PD and Food Effect Study of URC102 in Healthy Adults and Patients With Renal Impairment
A phase 1 clinical trial to evaluate safety, PK/PD profiles and food effects of URC102 in patients with renal impairment and healthy people.
- Trial name
- NCT05198778
- Testing
- URC102
- Where
- 2 sites in South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- JW Pharmaceutical
Diabetes Mellitus, Type 2
A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients
The purpose of the study is to evaluate the safety and tolerability of PF-05190457 after administration of multiple doses to healthy volunteers and Type 2 diabetic patients and to evaluate the plasma drug concentrations after…
- Trial name
- NCT01372163
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy, Epilepsy
Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
The human brain presents outstanding challenges to science and medicine. Brain function and structure span broad spatial scales (from single neurons to brain-wide networks) as well as temporal scales (from milliseconds to years).
- Conditions
- Healthy, Epilepsy, Psychosis, Essential Tremor
- Trial name
- NCT05769933
- Testing
- Simultaneous EEG-fMRI at 7 Tesla, Structural MRI at 7 Tesla
- Where
- Switzerland
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- CSEM Centre Suisse d'Electronique et de Microtechnique SA - Recherche et Developpement
Healthy Volunteers
Safety and Pharmacokinetics of Smoked Cannabis in Healthy Patients
No actual human data for pharmacokinetics, metabolism, safety, pharmacodynamics, nor efficacy parameters are available for inhaled medical cannabis.
- Trial name
- NCT04314804
- Testing
- PPP001
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Tetra Bio-Pharma
Hepatitis B
Study to Evaluate Induction of HBV Virus Neutralizing Antibodies Using VVX001
The Study will evaluate the effects of VVX001, a novel vaccine for hepatitis B, to elicit a robust protective IgG immune response in vaccine naive subjects in subjects who failed to demonstrate seroconversion after treatment with…
- Trial name
- NCT03625934
- Testing
- VVX001
- Where
- 2 sites in Austria
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Viravaxx AG
Kidney Failure, Chronic
Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects
A phase I, open-label study comparing the pharmacokinetics, pharmacodynamics, safety and tolerability of ticagrelor in hemodialysis patients to healthy subjects with normal renal function.
- Trial name
- NCT02022748
- Testing
- ticagrelor
- Where
- 2 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Heart Failure, Congestive
Evaluation of MRI Measures of Lung Water With Posture Changes in Healthy Volunteers and in Patients With Cardiac Failure
The aim of this study is to establish a model for the evaluation of drug targets using postural measures to induce changes in lung water concentration as assessed by MRI.
- Trial name
- NCT01277679
- Testing
- MRI
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
C3 Glomerulopathy (C3G), Healthy Adult Participants
A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy
This study is the first time the new medicine CPV-104 is being tested in people. CPV-104 is designed to regulate the complement system, which can be overactive in diseases such as C3 glomerulopathy (C3G), an ultra-rare kidney…
- Trial name
- Essential One (NCT07483827)
- Testing
- CPV-104
- Where
- 17 sites in Austria, Belgium and 10 more
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- eleva GmbH
Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD)
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
- Trial name
- NCT05395624
- Testing
- 18F-OP-801
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Ashvattha Therapeutics, Inc.
Coronary Heart Disease
Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)
The purpose of this study is to determine: (1) the safety and pharmacokinetics of APL180 administered as a single intravenous infusion in healthy volunteers, and (2) the safety, pharmacokinetics and pharmacodynamics of single and…
- Trial name
- NCT00568594
- Testing
- APL180
- Where
- 11 sites in United States, Belgium and 5 more
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Novartis
Myelofibrosis
Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects
This is an open-label, parallel-group, single-dose study of the PK and safety of 400 mg pacritinib administered orally to patients with stable chronic liver disease and healthy control subjects.
- Trial name
- NCT02765724
- Testing
- Pacritinib
- Where
- 2 sites in Germany, Moldova
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- CTI BioPharma
Ulcerative Colitis (UC)
Safety, Tolerability and PK of ATTO 1091 in Healthy Adult Volunteers and Patients With Ulcerative Colitis
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics (PK) of ATTO-1091 in healthy adults and patients with ulcerative colitis.
- Trial name
- NCT07819799
- Testing
- ATTO-1091
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Attovia Therapeutics Inc
Healthy
Effect of Severe Renal Impairment on Pharmacokinetics and Metabolism of a Single Administration of Licarbazepine
This study will assess the influence of severe renal impairment on the pharmacokinetics of licarbazepine and its glucuronide conjugate after single oral administration in healthy subjects and in subjects with stable impaired…
- Trial name
- NCT00426036
- Testing
- Licarbazepine
- Where
- Czechia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Novartis
Healthy, Sickle Cell Anemia
Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease
This Phase 1 first-in-human, first-in-patient, single ascending dose and multiple dose study will be a randomized, double-blind, placebo-controlled investigation of the safety, tolerability, and pharmacokinetics of PF-07209326 in…
- Trial name
- NCT04255875
- Testing
- PF-07209326
- Where
- 16 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type2 Diabetes
DCB-DM101 in Healthy Volunteers and for Type 2 Diabetes Mellitus Patients
An Open-Label Phase I Study to Assess the Safety and Tolerability Profile of Three Escalating Doses of DCB-DM101 in Healthy Volunteers and Optimum Dose of DCB-DM101 as Add-on Treatment in Type 2 Diabetes Mellitus (T2DM) Patients
- Trial name
- NCT03033433
- Testing
- DCB-DM101
- Where
- Taiwan
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- VitNovo, Inc.
Meningococcal Disease
Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.
The study aims at evaluating the safety and immunogenicity of rMenB+OMV NZ when administered to subjects from 2 to 17 years of age with increased risk of meningococcal disease because either of primary or secondary complement…
- Trial name
- NCT02141516
- Testing
- rMenB+OMV
- Where
- 20 sites in Italy, Poland and 3 more
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- Novartis
Hepatitis C
A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.
This study is a three Part, Phase 1, randomized, dose-escalation, fusion, placebo-controlled, double-blind study to determine the safety, tolerability and Pharmacokinetic (PK) profile of GSK2336805 in healthy subjects and the…
- Trial name
- NCT01277692
- Testing
- GSK2336805 10mg, GSK2336805 30mg, GSK2236805 100mg
- Where
- 3 sites in United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatic Impairment, Liver Disease
Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients
This study is being conducted in order to assess the need for dose adjustment for elafibranor in patients with hepatic impairment.
- Conditions
- Hepatic Impairment, Liver Disease, Pharmacokinetics
- Trial name
- NCT03765671
- Testing
- Elafibranor
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Genfit
Anogenital Warts
Systemic Exposure of Catechins From Veregen 15% Ointment in Patients With External Anogenital Warts and From Oral Intake of Green Tea Beverage in Healthy Volunteers
Investigation of systemic catechin exposure following topically administered Veregen® 15% ointment in patients with external genital and perianal warts and following oral intake of a standardized green tea beverage in healthy…
- Trial name
- NCT01490008
- Testing
- Veregen, Green Tea
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- MediGene
Healthy Volunteers, Psoriasis
A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Psoriasis
To assess safety and tolerability of multiple oral doses of BAY1834845 in healthy male subjects (Part 1) and in patients with psoriasis (Part 2).
- Trial name
- NCT03493269
- Testing
- BAY1834845, Midazolam
- Where
- 2 sites in Germany
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Bayer